LABORATORIOS FARMACEUTICOS ROVI, S.A. «12345» Page 4 out of 5 22/02/2022 14:47 LABORATORIOS FARMACEUTICOS ROVI, S.A. On share buy-back , stabilisation and treasury stock programmes The Company informs of the end of the share buy-back programme launched as of 3 November 2021, and of the launching of a new share buy-back programme, effective as of 23 February 2022. Register number: 1308 16/02/2022 07:42 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company informs of the expansion of the collaboration that currently exists between ROVI and Moderna for the manufacture of mRNA medicines Register number: 1299 03/11/2021 07:32 LABORATORIOS FARMACEUTICOS ROVI, S.A. On share buy-back , stabilisation and treasury stock programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Register number: 1143 16/07/2021 14:46 LABORATORIOS FARMACEUTICOS ROVI, S.A. On corporate governance Laboratorios Farmacéuticos Rovi, S.A. announces the appointment of Juan López-Belmonte Encina as Chairman of the Board of Directors Register number: 991 22/06/2021 20:07 LABORATORIOS FARMACEUTICOS ROVI, S.A. (LABORATORIOS ROVI) On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Register number: 948 22/06/2021 18:29 LABORATORIOS FARMACEUTICOS ROVI, S.A. (LABORATORIOS ROVI) On significant placements in financial instruments Bestinver announces the beginning of an acceralted book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Register number: 947 29/04/2021 07:05 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company announces that it increases its fill-finish capacity for the COVID-19 Vaccine Moderna Register number: 858 12/04/2021 08:35 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company publishes the press release concerning the extension of the collaboration that currently exists between ROVI and Moderna for the manufacture of the active substance of the COVID-19 Vaccine Moderna. Register number: 837 02/03/2021 08:10 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States Register number: 782 02/03/2021 08:06 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States. Register number: 781 Page 4 out of 5 «12345»